Show simple item record

dc.contributor.authorEngel, Jerome Jr
dc.contributor.authorPitkänen, Asla
dc.date.accessioned2020-03-16T11:18:10Z
dc.date.available2020-03-16T11:18:10Z
dc.date.issued2020
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/8060
dc.description.abstractThere are no pharmacological interventions to prevent the development of epilepsy, although many promising compounds have been identified in the animal laboratory. Clinical trials to validate their effectiveness, however, would currently be prohibitively expensive due to the large subject population and duration of follow-up necessary. There is, therefore, the need to identify biomarkers of epileptogenesis that could identify patients at high risk for epilepsy following a potential epileptogenic insult to enrich the subject population, as well as biomarkers that could determine the effectiveness of therapeutic intervention without the need to wait for seizures to occur. Putative biomarkers under investigation for epileptogenesis and its treatment include genetic, molecular, cellular, imaging, and electrophysiological measures that might reliably predict the development or progression of an epileptic condition, the effects of antiepileptogenic treatment, or cure after surgery. To be clinically useful for most purposes, ideal biomarkers should be noninvasive, and it is anticipated that a profile of multiple biomarkers will likely be required. Ongoing animal research involves a number of experimental models of epileptogenesis, with traumatic brain injury, offering the best potential for translational clinical investigations. Collaborative and multicenter research efforts by multidisciplinary teams of basic and clinical neuroscientists with access to robust, well-defined animal models, extensive patient populations, standardized protocols, and cutting-edge analytical methodologies are likely to be most successful. Such biomarker research should also provide insights into fundamental neuronal mechanisms of epileptogenesis suggesting novel targets for antiepileptogenic treatments. This article is part of the special issue entitled ‘New Epilepsy Therapies for the 21st Century – From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy’.
dc.language.isoenglanti
dc.publisherElsevier BV
dc.relation.ispartofseriesNeuropharmacology
dc.relation.urihttp://dx.doi.org/10.1016/j.neuropharm.2019.107735
dc.rightsCC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectantiepileptogenesis
dc.subjectarea under the curve
dc.subjectdiagnosis
dc.subjectelectroencephalogram
dc.subjectepileptogenesis
dc.subjectmagnetic resonance imaging
dc.subjectmicroRNA
dc.subjectreceiver operating characteristics
dc.titleBiomarkers For Epileptogenesis And Its Treatment
dc.description.versionfinal draft
dc.contributor.departmentA.I. Virtanen -instituutti
uef.solecris.id64309616en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© Elsevier Ltd.
dc.relation.doi10.1016/j.neuropharm.2019.107735
dc.description.reviewstatuspeerReviewed
dc.relation.articlenumber107735
dc.relation.issn0028-3908
dc.relation.volume167
dc.rights.accesslevelopenAccess
dc.type.okmA2
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record